Cover Image
市場調查報告書

軟骨肉瘤:開發中產品分析

Chondrosarcoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 246002
出版日期 內容資訊 英文 148 Pages
訂單完成後即時交付
價格
Back to Top
軟骨肉瘤:開發中產品分析 Chondrosarcoma - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 148 Pages
簡介

軟骨肉瘤是產生造成骨骼異常及軟骨成長的玻璃軟骨之惡性腫瘤。夜晚及運動時會產生疼痛、腫起、腫塊、患部運動障礙、排尿變化等。治療方法有化療及放射線療法。

本報告提供軟骨肉瘤的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

軟骨肉瘤概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

軟骨肉瘤:企業開發中的治療藥

軟骨肉瘤:大學/機關研究中的治療藥

軟骨肉瘤:開發中產品概況

  • 臨床階段的產品

軟骨肉瘤:企業開發中的產品

軟骨肉瘤:大學/機關研究中的產品

軟骨肉瘤的治療藥開發企業

  • Agios Pharmaceuticals, Inc.
  • Celgene Corporation
  • CytRx Corporation
  • EpiZyme, Inc.
  • Horizon Pharma Plc
  • Karyopharm Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG

軟骨肉瘤:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

軟骨肉瘤:最近的開發平台趨勢

軟骨肉瘤:暫停中的計劃

軟骨肉瘤:開發中止的產品

軟骨肉瘤:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8674IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chondrosarcoma - Pipeline Review, H2 2016, provides an overview of the Chondrosarcoma (Oncology) pipeline landscape.

Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, changes in urination. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chondrosarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chondrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chondrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.Chondrosarcoma.

Chondrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chondrosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Chondrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chondrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chondrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chondrosarcoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chondrosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chondrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chondrosarcoma Overview
  • Therapeutics Development
    • Pipeline Products for Chondrosarcoma - Overview
    • Pipeline Products for Chondrosarcoma - Comparative Analysis
  • Chondrosarcoma - Therapeutics under Development by Companies
  • Chondrosarcoma - Therapeutics under Investigation by Universities/Institutes
  • Chondrosarcoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Chondrosarcoma - Products under Development by Companies
  • Chondrosarcoma - Products under Investigation by Universities/Institutes
  • Chondrosarcoma - Companies Involved in Therapeutics Development
    • Agios Pharmaceuticals, Inc.
    • Celgene Corporation
    • CytRx Corporation
    • EpiZyme, Inc.
    • Horizon Pharma Plc
    • Karyopharm Therapeutics, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
  • Chondrosarcoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AG-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aldoxorubicin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • axitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • enasidenib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon gamma-1b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pazopanib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit c-Myc and mTOR for Chondrosarcoma and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tazemetostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chondrosarcoma - Dormant Projects
  • Chondrosarcoma - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chondrosarcoma, H2 2016
  • Number of Products under Development for Chondrosarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Chondrosarcoma - Pipeline by Agios Pharmaceuticals, Inc., H2 2016
  • Chondrosarcoma - Pipeline by Celgene Corporation, H2 2016
  • Chondrosarcoma - Pipeline by CytRx Corporation, H2 2016
  • Chondrosarcoma - Pipeline by EpiZyme, Inc., H2 2016
  • Chondrosarcoma - Pipeline by Horizon Pharma Plc, H2 2016
  • Chondrosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Chondrosarcoma - Pipeline by Merck & Co., Inc., H2 2016
  • Chondrosarcoma - Pipeline by Novartis AG, H2 2016
  • Chondrosarcoma - Pipeline by Pfizer Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chondrosarcoma - Dormant Projects, H2 2016
  • Chondrosarcoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Chondrosarcoma, H2 2016
  • Number of Products under Development for Chondrosarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top